Birla Institute of Technology, Mesra
Dr. S. Samanta
Professor, Pharmaceutical Sciences and Tech
M. Pharm., Ph.D.
Contact Address
Permanent Address Mesra
Local Address Mesra
Phone (Office) +919431596870
Phone Residence +919431596870
Email Id
Joined Institute on : 30-Sep-1985
  Work Experience
Teaching : 32 Years

Research : 33 Years

Individual: 33 Years

  Professional Background

Professor, Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi (01/10/1985 to Till Date) – Employee Code: 05806

  Research Areas

Research involving Design, Molecular Modeling (Using Glide and FelxX), Synthesis of peptides and hybrid compounds, Studies on antidiabetics, diabetic-cardiomyopathy, hepatoprotectives, analagesics, antirhuematics, and anti-cancer (liver) Compounds.

  Award and Honours

Member, “The research board of advisor in the American Biographical Institute’ USA 2006.

  1. Nagranjan K., S. Samanta, S.Parthiban, R. Uma Maheswari, “Pharmacological evaluation of small Chain dipedtides and tripeptides in alloxanized rabbits” Hamdard medicines 14th Jan.-Mar. Edn. 2007.
  2. T.R. Juneja, R.L. Gupta and Subir Samanta, “Activation of Monocrotaline Fulvine and their derivatives of toxic pyrroles by some thiols” Toxicology letters, 21, pp. 185-189, 1984 published by Elsevier, Amsterdam.
  3. S.P. Gupta, S. Samanta and V.M. Patil, “A 3D –QSAR studies on series of benzimidazole Derivatives acting as Hepatitis C Virus Inhibitors: Application of kNN-Molecular Field Analysis”. Medicinal Chemistry, 2010, 6, 87-90.
  4. V.M. Patil, S.P. Gupta, S. Samanta and N. Masand, “A 3D –QSAR kNN MFA Studies on thiouracil derivatives as hepatitis C virus inhibitors” Medicinal Chemistry Research, 2010, 1-6.
  5. V.M. Patil, S.P. Gupta, S. Samanta, “A QSAR Study on a series of anti Hepatitis C virus (HCV) Agents”. Letters in Drug Design and Discovery, 2010, 7, 139-148.
  6. V.M. Patil, S.P. Gupta, S. Samanta and N. Masand, “Current Perspective of HCV NS5B inhibitors: A Review”. Current Medicinal Chemistry, 2011, 18, 5564-5597.
  7. Vaishali M. Patil, Neeraj Masand, S.P. Gupta, S. Samanta and Neeral Masand; 3D QSAR kNN-MFA studies on thiouracil derivatives as hepatitis C virus inhibitors, Med. Chem. Res. 2011, 20:1616-1621.
  8. S. Samanta, S.P. Gupta, N. Masand, N.K. Basu and V.M. Patil, “Docking Directed kNN MFA study of Pyrimidine Nucleosides as HCV NS5B Inhibitors”. International Journal of Drug Designing and Discovery, 2012, 3, 2, 809-813.
  9. V.M. Patil, K.R.Gurukul, M. Chedayeu, S.P. Gupta, S. Samanta and N. Masand, and N.K. Basu, “Synthesis in vivo and in silico NS5B Polymerase Inhibitors activity of Benzimidazole derivatives. Medicinal Chemistry 2012, 8, 1-7.
  10. Banerjee P.S., Samanta S., A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonistis. Mini-Review in Medicinal Chemistry 2013, 13, 5, 706-712.
  11. Patil V.M., Gupta S.P., Samanta S., Masand N., Virtual screening of imidazole analogs as potential hepatitis C virus NS5B polymerase inhibitors, Chemical Papers Verista, 2013, 67 (2) 236-244.
  12. Gupta S.P., Samanta S., Masand Neeraj, Patil V.M., k nearest neighbor – molecular field analysis on human HCV NS5B polymerase inhibitors: 2, 5-disubstituted imidazole [4,5-c] pyridines. Medicinal Chemistry Research 2013, 1, 22, 330-339.
  13. Prakash S., Maji D., Samanta S., and Shina R.K., Design Synthesis and Antidiabetic, Cardiomyopathy Studies of Cinnamic Acid-Amino Acid Hybrid Analogs. Med. Chem. 2014, 4:2, 345-350.
  14. Biswaranjan Das and Subir Samanta, Chalcon as potent molecule: Anti-inflammatory, Antiarthtitic, Antioxidant and Antiulcer: A Review. International Journal of Pharmaceutical Research 2015,7:1, 1-8.
  15. Biswaranjan Das and Subir Samanta, Molecular target and therapeutic aspects of rheumatoid arthritis: A Review, Asian Journal of Pharmaceutical and Clinical Research 2015, 8:2, 32-40.
  16. Subir Samanta, S. Burle, “In silico design and discovery of some novel hybrid amino acid analogs for their hepatoprotective activity. International Journal of Pharmaceutical Research 2015, 7(4), 7-15.
  17. Maji D., Samanta S., A Review on the Role of PPARγ Agonists and Hybrids in Type 2 Diabates and Cardiomyopathy. Asian J. Pharm. Clin. Res. 2015, 8, 26-31, (Indexed in SCOPUS).
  18. Maji D., Samanta S., In-Silico ADMET and Docking Studies of 2, 4 Dioxothiazolidine – 5-Carboxylic Acid Amino acid and Dipeptide Hybrid methyl esters as Potent Antidiabetic and Cardioprotective Agents using FlexX 2.1.3. Int. J. Pharm. Res. 2015, 7 (4), 16-23. (Indexed in SCOPUS).
  19. Chacko S., Samanta S., Novel thiosemicarbazide hybrids with amino acids and peptides against hepatocellular carcinoma: A molecular designing approach towards multikinase inhibitor. Current computer aided drug design 2015, 11(3), 279-290. SCI – expanded and Scopus Indexed (Impact Factor – 1.3).
  20. Chacko S., Samanta S., Hepatocellular carcinoma: A life-threatening disease. Biomedicine & Pharmacotherapy 2016, 84, 1679-1688.  SCI and Scopus Indexed (Impact Factor – 2.32).
  21. Chacko S., Samanta S., A novel approach towards design, synthesis and evaluation of some Schiff base analogues of 2-aminopyridine and 2-amniobenzothiazole against hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2017, DOI: 10.1016/j.biopha.2017.01.108. SCI and Scopus Indexed (Impact Factor – 2.32).
  22. D. Maji, S. Samanta. Novel thiazolidinedione-5-acetic-acid-peptide hybrid derivatives as potent antidiabetic and cardioprotective agents. Biomedicine & Pharmacotherapy 88 (2017) 1163–1172. DOI: SCI and Scopus Indexed (Impact Factor – 2.33).


  Member of Professional Bodies
  1. Life member of the Association of Pharmaceutical Teachers of India.
  2. Life members of I.S.T.E. I.I.T., Delhi.
  3. Member Indian Pharmaceutical Association.


  Current Sponsored Projects


  1. Patent Certificate - granted on 25th March 2009. Novel orally administrable antidiabetic compounds, process for producing them and therapeutic compositions containing the same – published in Patent Journal, October, 2006.
  2. “Novel Antidiabetic and Cardioprotective Compounds Containing Thiazolidinedione – Amino – acid and Peptide Analogues” Application No. 201631013454 dated 18.04.2016.